Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 9/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 7/20 | 1.00 |
| ▸ | TUBB | P07437 | 7/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 7/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 7/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 7/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 7/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 7/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 7/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 7/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 7/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 7/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 7/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 7/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 7/20 | 1.00 |
| ▸ | TOP2A | P11388 | 2/20 | 0.85 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12402700 | 0.94 | TUBB1 (0.88) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL12831823 | 0.93 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Thiocolchicine SCHEMBL43161 | 0.93 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Thiocolchicine SCHEMBL43160 | 0.93 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Colchicine SCHEMBL2723855 | 0.90 | TUBB1 (0.95) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| 2-Desmethylcolchicin SCHEMBL2007529 | 0.90 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8151606 | 0.89 | TUBB4A (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2146635 | 0.89 | TUBB4A (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29470574 | 0.89 | TUBB4A (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13622271 | 0.89 | TUBB1 (0.80) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0356137-B1 | Carbonates of 3-demethylthiocolchicine and N-acyl analogs | ADVANCE BIOFACTURES CORP (US) | 1994-10-26 | — | — | EP | claimed |
| EP-0356137-A2 | Carbonates of 3-demethylthiocolchicine and N-acyl analogs | Advance Biofactures Corporation (US) | 1990-02-28 | — | — | EP | claimed |
| JP-2142765-A | — | — | None | — | — | JP | disclosed |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | NOVARTIS AG (CH) | 2026-05-12 | — | — | US | disclosed |
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | NOVARTIS AG (CH) | 2026-02-05 | — | — | US | disclosed |
| US-20250326855-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250304716-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250223359-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2025-07-10 | — | — | US | disclosed |
| US-12324799-B2 | Methods and uses of colchicine derivatives | ALBERTA HEALTH SERVICES (CA) | 2025-06-10 | — | — | US | disclosed |
| US-20250136701-A1 | ANTI-GLYCO-CMET ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| US-12275795-B2 | Binding molecules against BCMA and uses thereof | NOVARTIS AG (CH) | 2025-04-15 | — | — | US | disclosed |
| EP-0356137-B1 | Carbonates of 3-demethylthiocolchicine and N-acyl analogs | ADVANCE BIOFACTURES CORP (US) | 1994-10-26 | — | — | EP | disclosed |
| US-5175342-A | Antiinflammatory agent, liver disorders, gout | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1992-12-29 | — | — | US | disclosed |
| US-5175342-A | Antiinflammatory agent, liver disorders, gout | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1992-12-29 | — | — | US | disclosed |
| US-5175342-A | Antiinflammatory agent, liver disorders, gout | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1992-12-29 | — | — | US | disclosed |
| JP-H02142765-A | ESTER OF 3-DEMETHYLTHIOCOLCHICINE AND N-ACYL ANALOGUE | ADVANCE BIOFACTURES CORP | 1990-05-31 | — | — | JP | disclosed |
| EP-0356137-A2 | Carbonates of 3-demethylthiocolchicine and N-acyl analogs | Advance Biofactures Corporation (US) | 1990-02-28 | — | — | EP | disclosed |
| EP-0356137-A2 | Carbonates of 3-demethylthiocolchicine and N-acyl analogs | Advance Biofactures Corporation (US) | 1990-02-28 | — | — | EP | disclosed |
| EP-0356137-A2 | Carbonates of 3-demethylthiocolchicine and N-acyl analogs | Advance Biofactures Corporation (US) | 1990-02-28 | — | — | EP | disclosed |
| US-4692463-A | LOW TOXICITY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1987-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136701-A1 | ANTI-GLYCO-CMET ANTIBODIES AND THEIR USES | CD2BP2, CSGALNACT1, DNTT | TUBB1 2729/4885TUBB4A 2056/4885TUBB 2196/4885 |
| US-12324799-B2 | Methods and uses of colchicine derivatives | IL1B, IL6, TUBB | TUBB1 4/4885TUBB4A 18/4885TUBB 3/4885 |
| US-20250326855-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | CD44, SIGLEC7, SIGLEC9 | TUBB1 2028/4885TUBB4A 1760/4885TUBB 1768/4885 |
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | BCL9, BRCA1, VCAM1 | TUBB1 2143/4885TUBB4A 3054/4885TUBB 3051/4885 |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | CD2, CD40, CD22 | TUBB1 1694/4885TUBB4A 1420/4885TUBB 1716/4885 |
| US-20250223359-A1 | CD19 BINDING MOLECULES AND USES THEREOF | CD22, BCL9, CD2 | TUBB1 1403/4885TUBB4A 1623/4885TUBB 1354/4885 |
| US-12275795-B2 | Binding molecules against BCMA and uses thereof | EPCAM, CD40, BCR | TUBB1 2744/4885TUBB4A 2438/4885TUBB 2534/4885 |
| US-20250304716-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | MUC1, SIGLEC7, SIGLEC9 | TUBB1 1740/4885TUBB4A 1391/4885TUBB 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.